Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta …
Drug Manufacturers - Specialty & Generic
US, Stoughton [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Collegium Pharmaceutical, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2016 | -2.0100 | -3.950 | 0 | 2 | -27 | -165 | -26 | 0.39 | -27 | 0.09 | 18 | 0.84 |
| 2017 | -3.8800 | -2.527 | 1 | 27 | -94 | -105 | -93 | 4 | -94 | -1 | 80 | 10 |
| 2018 | -2.4700 | -1.336 | 28 | 279 | -74 | -16 | -74 | 122 | -75 | 2 | 92 | 154 |
| 2019 | -1.1900 | 0.144 | 280 | 295 | -39 | -21 | 91 | -4 | -20 | -22 | 126 | 118 |
| 2020 | -0.2400 | 3.754 | 296 | 311 | -8 | 23 | -6 | 120 | -23 | 54 | 116 | 131 |
| 2021 | 0.7800 | 3.842 | 310 | 332 | 26 | 54 | 118 | 75 | 56 | -21 | 113 | 163 |
| 2022 | 2.0500 | 4.332 | 276 | 459 | 71 | -81 | 86 | 102 | 22 | -65 | 118 | 274 |
| 2023 | -0.7400 | 5.210 | 463 | 564 | -25 | 48 | 168 | 112 | 33 | -71 | 172 | 302 |
| 2024 | 1.6000 | 6.163 | 566 | 628 | 48 | 257 | 308 | 198 | 166 | 66 | 159 | 231 |
| 2025 | - | 6.578 | - | 739 | - | 275 | - | 233 | - | 77 | - | 272 |
| 2026 | - | 2.F10X/td> | - | 2.F10X/td> | - | 2.F10X/td> | - | 2.F101/td> | - | 2.F101 | - | 2.F101 |
| 2027 | - | 1.F11X/td> | - | 1.F11X/td> | - | 1.F11X/td> | - | 1.F111/td> | - | 1.F111 | - | 1.F111 |
| 2028 | - | 0.F12X/td> | - | 0.F12X/td> | - | 0.F12X/td> | - | 0.F121/td> | - | 0.F121 | - | 0.F121 |